On October 17, Caitlin Sheetz, ADVI solution leader for Strategic Analytics, Value and Economics (SAVEs), presented an award-winning abstract on the Inflation Reduction Act (IRA) at the Academy of Managed Care Pharmacy (AMCP)’s Nexus conference.

This groundbreaking study, which was recognized by AMCP with a Platinum Award, evaluated the profound effects of the Inflation Reduction Act (IRA) and the $2,000 out-of-pocket spending cap on Medicare Part D beneficiaries.

This study marks ADVI’s first look into the patient population influenced by the new Part D benefit design and emphasizes the significant proportion of patients taking one of the first ten drugs subject to price negotiation who exceed the out-of-pocket threshold.

Hear more from Caitlin as she sheds light on key insights from the study and takeaways from AMCP Nexus. You can also view the poster for the presentation here: ADVI AMCP Nexus 2023 Poster.

Learn More

ADVI experts will continue to analyze the impact of the IRA as the new Part D benefit design and drug price negotiations evolve. Get in touch today to gain expert insights on the Inflation Reduction Act and the evolving healthcare landscape.